Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2025-03-24 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
普莱柯关于获得新兽药注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a new veterinary drug registration certificate from the Ministry of Agriculture and Rural Affairs. It details the product information, development background, and regulatory compliance steps. The text is an official announcement of a regulatory approval event, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. The document length is short (1728 characters) and it serves as a formal notification to shareholders and the public about a regulatory milestone. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-03-24 Chinese
普莱柯关于获得新兽药注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company about obtaining a new veterinary drug registration certificate. It details the new drug's name, components, research and development background, market context, and the impact on the company. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory announcement about a new product approval, not a financial report or meeting material. It fits best under Regulatory Filings (RNS) as it is a formal regulatory announcement that does not fit other specific categories.
2025-03-24 Chinese
普莱柯股东减持股份结果公告
Director's Dealing Classification · 100% confidence The document is a shareholder announcement regarding the completion of a shareholding reduction by a company director and senior management member. It details the number of shares held before and after the reduction, the reduction plan, and its implementation results. The document is short (1260 characters) and focuses on insider share transactions rather than financial results or corporate governance changes. It matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades).
2025-02-12 Chinese
普莱柯2024年年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2024 annual performance forecast (业绩预告) from 普莱柯生物工程股份有限公司, providing preliminary estimated net profit figures for the full year 2024 with comparisons to the prior year. It explicitly states that the data is preliminary, unaudited, and that the final accurate financial data will be disclosed in the formal 2024 annual report. The document is short (1179 characters) and serves as an earnings guidance or forecast rather than a full financial report. This type of document is best classified as an Earnings Release (ER), which covers initial announcements of periodic financial results or forecasts with key highlights only, not the full detailed report.
2025-01-17 Chinese
普莱柯股东减持股份计划公告
Director's Dealing Classification · 100% confidence The document is a public announcement regarding a shareholder's plan to reduce their shareholding in the company. It details the shareholder's identity, the number of shares held, the planned reduction amount, the method of reduction, the timing, and associated risks. It specifically mentions the shareholder is a director and senior management, and the announcement includes compliance with regulatory guidelines on share reduction. There are no financial statements, earnings data, or report attachments. The document is a notification of a director's personal share transaction plan (share reduction). Therefore, it fits the category of Director's Dealing (DIRS). The document length is short and focused solely on this shareholding reduction plan, confirming it is not a full financial report or other type of filing.
2025-01-09 Chinese
普莱柯关于获得新兽药注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a new veterinary drug registration certificate. It details the product information, regulatory approval, and the impact on the company. There are no financial statements, earnings data, or management discussion of financial results. The document is an official announcement about a regulatory approval related to product registration, not a financial report or meeting material. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-01-07 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.